SEC Company Response from PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101) (PLSE) — Jul 7, 2017
PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101)
Date: July 7, 2017 · CIK: 0001625101 · Accession: 0001625101-17-000021
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-219096
Letter
Resale S-3 - Acceleration Request Letter
July 7, 2017
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention:
Amanda Ravitz
Heather Percival
Re:
Pulse Biosciences, Inc.
Registration Statement on Form S-3
Filed June 30, 2017
File No. 333-219096
Acceleration Request
Requested Date:
July 11, 2017
Requested Time:
4:00 PM Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pulse Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-219096) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Company may request by telephone to the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes Andrew D. Hoffman of Wilson Sonsini Goodrich & Rosati, Professional Corporation, counsel for the Company, to make such request on the Company’s behalf.
The Company requests that it be notified of the effectiveness of the Registration Statement by telephone to Andrew D. Hoffman of Wilson Sonsini Goodrich & Rosati, Professional Corporation, at (650) 849-3240. Please also provide a copy of the Commission’s order declaring the Registration Statement effective to Andrew D. Hoffman via facsimile at (650) 493-6811.
Please direct any questions or comments regarding this acceleration request to Andrew D. Hoffman at (650) 849-3240.
*****
Securities and Exchange Commission
Re: Pulse Biosciences, Inc.
July 7, 2017
Page 2
Sincerely,
Show Raw Text
CORRESP 1 filename1.htm Resale S-3 - Acceleration Request Letter July 7, 2017 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Amanda Ravitz Heather Percival Re: Pulse Biosciences, Inc. Registration Statement on Form S-3 Filed June 30, 2017 File No. 333-219096 Acceleration Request Requested Date: July 11, 2017 Requested Time: 4:00 PM Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pulse Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-219096) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Company may request by telephone to the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes Andrew D. Hoffman of Wilson Sonsini Goodrich & Rosati, Professional Corporation, counsel for the Company, to make such request on the Company’s behalf. The Company requests that it be notified of the effectiveness of the Registration Statement by telephone to Andrew D. Hoffman of Wilson Sonsini Goodrich & Rosati, Professional Corporation, at (650) 849-3240. Please also provide a copy of the Commission’s order declaring the Registration Statement effective to Andrew D. Hoffman via facsimile at (650) 493-6811. Please direct any questions or comments regarding this acceleration request to Andrew D. Hoffman at (650) 849-3240. ***** Securities and Exchange Commission Re: Pulse Biosciences, Inc. July 7, 2017 Page 2 Sincerely, PULSE BIOSCIENCES, INC. By: /s/ Brian B. Dow Brian B. Dow Senior Vice President and Chief Financial Officer cc: Andrew D. Hoffman, Esq. Wilson Sonsini Goodrich & Rosati, Professional Corporation